Clinical Trial Update: Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL [Phase 1, Phase 2]

View source ↗

Summary

Open-label extension study of de-immunized DI-Leu16-IL2 immunocytokine in participants with B-cell non-Hodgkin lymphoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• DI-Leu16-IL2 (DI-Leu16-IL2)

Snippet

Sponsor: Alopexx Oncology, LLC | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-11-27